Suggested Readings

Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study.

Deodar A, et al. Arthritis Rheumatol. 2021;73(1):110-120.

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.

Deodar A, et al; COAST-X Study Group. Lancet. 2020;395(10217):53-64.

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.

Deodhar A, et al.  Ann Rheum Dis. 2021;80(8):1004-1013.

Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Deodhar A, et al. Lancet. 2022;400(10349):369-379.

Have therapeutics enhanced our knowledge of axial spondyloarthritis?

Harrison SR, Marzo-Ortega H. Curr Rheumatol Rep. 2023;25(3):56-67.

Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial.

Molto A, et al. Ann Rheum Dis. 2021;80(11):1436-1444.

Janus kinase inhibitors: a new tool for the treatment of axial spondyloarthritis.

Paroli M, et al. Int J Mol Sci. 2023;24(2):1027.

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.

van der Heijde D, et al. Ann Rheum Dis. 2022;81(11):1515-1523.

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension.

van der Heijde D, et al. RMD Open. 2022;8(2):e002280.

Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis.

Ytterberg SR, et al. ORALSurveillance Investigators. N Engl J Med. 2022;386(4):316-326.

Linked Resources

Clinical Practice Guidelines

2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

Ward MM, et al. Arthritis Rheumatol. 2019;71(10):1599-1613.

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.

Ramiro S, et al. Ann Rheum Dis. 2023;82(1):19-34.

Clinical Resources

Spondylitis Resources and Information for Medical Professionals

Spondylitis Association of America

Education and Training Opportunities

Educational Activities

American College of Rheumatology

Patient Resources

Serving the Spondyloarthritis Community

Spondylitis Association of America (SAA)

SAA is a nationwide nonprofit organization that educates, empowers, and advocates for people living with spondylitis and its related diseases. Through its partnership with patients and the medical community, SAA provides extensive resources and champions research to find a cure.

Project Nightingale

The Nightingale study is designed to empower people with AxSpA to take control of their symptoms and improve their quality of life. Real-time data gathered via the uMotif app tracks exercise, sleep, and other factors, allowing a level of disease self-management.

Related activities

AxSpA Boot Camp: Are You Up to Date on Recent Advances?

A CME Circuit Training™ Activity

Faculty: Alexis R. Ogdie, MD, MSCE
Release: 07/28/2023
Expiration: 07/28/2024